Van Assche G - Search Results

1

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.

Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A. Van Stappen T, et al. Among authors: van assche g. Gut. 2018 May;67(5):818-826. doi: 10.1136/gutjnl-2016-313071. Epub 2017 Apr 27. Gut. 2018. PMID: 28450388 Clinical Trial.

2

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Vermeire S, et al. Among authors: van assche g. Gut. 2007 Sep;56(9):1226-31. doi: 10.1136/gut.2006.099978. Epub 2007 Jan 17. Gut. 2007. PMID: 17229796 Free PMC article.

3

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

Rutgeerts P, Vermeire S, Van Assche G. Rutgeerts P, et al. Among authors: van assche g. Gut. 2007 Apr;56(4):453-5. doi: 10.1136/gut.2005.088732. Gut. 2007. PMID: 17369375 Free PMC article. Review.

4

Predicting the response to infliximab from trough serum levels.

Rutgeerts P, Vermeire S, Van Assche G. Rutgeerts P, et al. Among authors: van assche g. Gut. 2010 Jan;59(1):7-8. doi: 10.1136/gut.2009.191411. Gut. 2010. PMID: 20007955 No abstract available.

5

Management of acute severe ulcerative colitis.

Van Assche G, Vermeire S, Rutgeerts P. Van Assche G, et al. Gut. 2011 Jan;60(1):130-3. doi: 10.1136/gut.2009.192765. Epub 2010 Oct 28. Gut. 2011. PMID: 21030524 Review.

6

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.

Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P. Van Assche G, et al. Gut. 2012 Feb;61(2):229-34. doi: 10.1136/gutjnl-2011-300755. Epub 2011 Sep 23. Gut. 2012. PMID: 21948942 Clinical Trial.

7

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Vande Casteele N, et al. Among authors: van steen k, van assche g. Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24. Gastroenterology. 2015. PMID: 25724455 Clinical Trial.

8

Immunogenicity to infliximab is associated with HLA-DRB1.

Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, Ferrante M, Van Assche G, Cleynen I, Vermeire S. Billiet T, et al. Among authors: van stappen t, van assche g. Gut. 2015 Aug;64(8):1344-5. doi: 10.1136/gutjnl-2015-309698. Epub 2015 Apr 15. Gut. 2015. PMID: 25876612 No abstract available.

9

Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.

Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, Ferrante M, Gils A. Detrez I, et al. Among authors: van stappen t, van assche g. J Crohns Colitis. 2016 May;10(5):575-81. doi: 10.1093/ecco-jcc/jjv241. Epub 2016 Jan 6. J Crohns Colitis. 2016. PMID: 26738756 Free PMC article.

10

Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.

Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Papamichael K, et al. Among authors: van assche g. J Crohns Colitis. 2016 Sep;10(9):1015-23. doi: 10.1093/ecco-jcc/jjw067. Epub 2016 Mar 28. J Crohns Colitis. 2016. PMID: 27022161

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

399 results

Search Page

Filters